Effect of rivaroxaban for anti-atherosclerotic response in atrial fibrillation patients

Effect of rivaroxaban for anti-atherosclerotic response in atrial fibrillation patients - Effect of rivaroxaban for anti-atherosclerotic response in atrial fibrillation patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011129

Enrollment

Registered

2013-07-05

Start date

2012-10-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Pescribe rivaroxaban15mg or 10mg once daily , according to renal function

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: nonvalvular atrial fibrillation

Exclusion criteria

Exclusion criteria: High risk for bleeding Liver dysfunction Renal failure Pregnancy severe infection and trauma, perioperation Treatment with HIV protease inhibitors Treatment with azole antifungal agents History of allergy to rivaroxaban Ineligible in the opinion of investigators

Design outcomes

Primary

Measure	Time frame
Change of inflammatory cytokine Transition of blood coagulation and fibrinolysis	—

Secondary

Measure	Time frame
Evaluation of IMT by carotid artery echo Evaluation of atherosclerotic plaque volume and character	—

Countries

Japan

Contacts

Public ContactSei Nakata

Yokohama Sakae Kyosai Hospital Division of Cardiology, Department of Internal Medicine

i-michishita@yokohamasakae.jp045-891-2171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026